🇺🇸 NicoDerm CQ Patch in United States

34 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 34

Most-reported reactions

1. Application Site Pruritus — 8 reports (23.53%)
2. Application Site Erythema — 5 reports (14.71%)
3. Application Site Pain — 3 reports (8.82%)
4. Application Site Urticaria — 3 reports (8.82%)
5. Drug Administration Error — 3 reports (8.82%)
6. Drug Ineffective — 3 reports (8.82%)
7. Hypersensitivity — 3 reports (8.82%)
8. Application Site Rash — 2 reports (5.88%)
9. Application Site Swelling — 2 reports (5.88%)
10. Dermatitis Contact — 2 reports (5.88%)

Source database →

Frequently asked questions

Is NicoDerm CQ Patch approved in United States?

NicoDerm CQ Patch does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for NicoDerm CQ Patch in United States?

Chrono Therapeutics, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.